0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Central Nervous System Disease Drugs Market Research Report 2025
Published Date: May 2025
|
Report Code: QYRE-Auto-12Q14328
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Central Nervous System Disease Drugs Market Research Report 2023
BUY CHAPTERS

Global Central Nervous System Disease Drugs Market Research Report 2025

Code: QYRE-Auto-12Q14328
Report
May 2025
Pages:100
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Central Nervous System Disease Drugs Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Central Nervous System Disease Drugs Market

Central Nervous System Disease Drugs Market

The global market for Central Nervous System Disease Drugs was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Central Nervous System Disease Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Central Nervous System Disease Drugs.
The Central Nervous System Disease Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Central Nervous System Disease Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Central Nervous System Disease Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Central Nervous System Disease Drugs Market Report

Report Metric Details
Report Name Central Nervous System Disease Drugs Market
CAGR 5%
Segment by Type
  • Antidepressants
  • Antipsychotics
  • Anti-Dementia Drugs
  • Anti-Parkinson's Drugs
  • Antiepileptic Drugs
  • Others
Segment by Application
  • Hospital and Clinic
  • Pharmacy
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Pfizer, Biogen, Otsuka, Novartis, Teva Pharmaceutical, Johnson & Johnson, AstraZeneca, Merck, GSK, Eli Lilly and Company, Lundbeck, Takeda, Bristol Myers Squibb, Jiangsu Nhwa Pharmaceutical, Luye Pharma, Zhejiang Huahai Pharmaceutical, Chengdu Easton Biopharmaceuticals, Hansoh Pharmaceutical
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Central Nervous System Disease Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Central Nervous System Disease Drugs Market report?

Ans: The main players in the Central Nervous System Disease Drugs Market are Pfizer, Biogen, Otsuka, Novartis, Teva Pharmaceutical, Johnson & Johnson, AstraZeneca, Merck, GSK, Eli Lilly and Company, Lundbeck, Takeda, Bristol Myers Squibb, Jiangsu Nhwa Pharmaceutical, Luye Pharma, Zhejiang Huahai Pharmaceutical, Chengdu Easton Biopharmaceuticals, Hansoh Pharmaceutical

What are the Application segmentation covered in the Central Nervous System Disease Drugs Market report?

Ans: The Applications covered in the Central Nervous System Disease Drugs Market report are Hospital and Clinic, Pharmacy

What are the Type segmentation covered in the Central Nervous System Disease Drugs Market report?

Ans: The Types covered in the Central Nervous System Disease Drugs Market report are Antidepressants, Antipsychotics, Anti-Dementia Drugs, Anti-Parkinson's Drugs, Antiepileptic Drugs, Others

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Central Nervous System Disease Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Antidepressants
1.2.3 Antipsychotics
1.2.4 Anti-Dementia Drugs
1.2.5 Anti-Parkinson's Drugs
1.2.6 Antiepileptic Drugs
1.2.7 Others
1.3 Market by Application
1.3.1 Global Central Nervous System Disease Drugs Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital and Clinic
1.3.3 Pharmacy
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Central Nervous System Disease Drugs Market Perspective (2020-2031)
2.2 Global Central Nervous System Disease Drugs Growth Trends by Region
2.2.1 Global Central Nervous System Disease Drugs Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Central Nervous System Disease Drugs Historic Market Size by Region (2020-2025)
2.2.3 Central Nervous System Disease Drugs Forecasted Market Size by Region (2026-2031)
2.3 Central Nervous System Disease Drugs Market Dynamics
2.3.1 Central Nervous System Disease Drugs Industry Trends
2.3.2 Central Nervous System Disease Drugs Market Drivers
2.3.3 Central Nervous System Disease Drugs Market Challenges
2.3.4 Central Nervous System Disease Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Central Nervous System Disease Drugs Players by Revenue
3.1.1 Global Top Central Nervous System Disease Drugs Players by Revenue (2020-2025)
3.1.2 Global Central Nervous System Disease Drugs Revenue Market Share by Players (2020-2025)
3.2 Global Central Nervous System Disease Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Central Nervous System Disease Drugs Revenue
3.4 Global Central Nervous System Disease Drugs Market Concentration Ratio
3.4.1 Global Central Nervous System Disease Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Central Nervous System Disease Drugs Revenue in 2024
3.5 Global Key Players of Central Nervous System Disease Drugs Head office and Area Served
3.6 Global Key Players of Central Nervous System Disease Drugs, Product and Application
3.7 Global Key Players of Central Nervous System Disease Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Central Nervous System Disease Drugs Breakdown Data by Type
4.1 Global Central Nervous System Disease Drugs Historic Market Size by Type (2020-2025)
4.2 Global Central Nervous System Disease Drugs Forecasted Market Size by Type (2026-2031)
5 Central Nervous System Disease Drugs Breakdown Data by Application
5.1 Global Central Nervous System Disease Drugs Historic Market Size by Application (2020-2025)
5.2 Global Central Nervous System Disease Drugs Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Central Nervous System Disease Drugs Market Size (2020-2031)
6.2 North America Central Nervous System Disease Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Central Nervous System Disease Drugs Market Size by Country (2020-2025)
6.4 North America Central Nervous System Disease Drugs Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Central Nervous System Disease Drugs Market Size (2020-2031)
7.2 Europe Central Nervous System Disease Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Central Nervous System Disease Drugs Market Size by Country (2020-2025)
7.4 Europe Central Nervous System Disease Drugs Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Central Nervous System Disease Drugs Market Size (2020-2031)
8.2 Asia-Pacific Central Nervous System Disease Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Central Nervous System Disease Drugs Market Size by Region (2020-2025)
8.4 Asia-Pacific Central Nervous System Disease Drugs Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Central Nervous System Disease Drugs Market Size (2020-2031)
9.2 Latin America Central Nervous System Disease Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Central Nervous System Disease Drugs Market Size by Country (2020-2025)
9.4 Latin America Central Nervous System Disease Drugs Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Central Nervous System Disease Drugs Market Size (2020-2031)
10.2 Middle East & Africa Central Nervous System Disease Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Central Nervous System Disease Drugs Market Size by Country (2020-2025)
10.4 Middle East & Africa Central Nervous System Disease Drugs Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Central Nervous System Disease Drugs Introduction
11.1.4 Pfizer Revenue in Central Nervous System Disease Drugs Business (2020-2025)
11.1.5 Pfizer Recent Development
11.2 Biogen
11.2.1 Biogen Company Details
11.2.2 Biogen Business Overview
11.2.3 Biogen Central Nervous System Disease Drugs Introduction
11.2.4 Biogen Revenue in Central Nervous System Disease Drugs Business (2020-2025)
11.2.5 Biogen Recent Development
11.3 Otsuka
11.3.1 Otsuka Company Details
11.3.2 Otsuka Business Overview
11.3.3 Otsuka Central Nervous System Disease Drugs Introduction
11.3.4 Otsuka Revenue in Central Nervous System Disease Drugs Business (2020-2025)
11.3.5 Otsuka Recent Development
11.4 Novartis
11.4.1 Novartis Company Details
11.4.2 Novartis Business Overview
11.4.3 Novartis Central Nervous System Disease Drugs Introduction
11.4.4 Novartis Revenue in Central Nervous System Disease Drugs Business (2020-2025)
11.4.5 Novartis Recent Development
11.5 Teva Pharmaceutical
11.5.1 Teva Pharmaceutical Company Details
11.5.2 Teva Pharmaceutical Business Overview
11.5.3 Teva Pharmaceutical Central Nervous System Disease Drugs Introduction
11.5.4 Teva Pharmaceutical Revenue in Central Nervous System Disease Drugs Business (2020-2025)
11.5.5 Teva Pharmaceutical Recent Development
11.6 Johnson & Johnson
11.6.1 Johnson & Johnson Company Details
11.6.2 Johnson & Johnson Business Overview
11.6.3 Johnson & Johnson Central Nervous System Disease Drugs Introduction
11.6.4 Johnson & Johnson Revenue in Central Nervous System Disease Drugs Business (2020-2025)
11.6.5 Johnson & Johnson Recent Development
11.7 AstraZeneca
11.7.1 AstraZeneca Company Details
11.7.2 AstraZeneca Business Overview
11.7.3 AstraZeneca Central Nervous System Disease Drugs Introduction
11.7.4 AstraZeneca Revenue in Central Nervous System Disease Drugs Business (2020-2025)
11.7.5 AstraZeneca Recent Development
11.8 Merck
11.8.1 Merck Company Details
11.8.2 Merck Business Overview
11.8.3 Merck Central Nervous System Disease Drugs Introduction
11.8.4 Merck Revenue in Central Nervous System Disease Drugs Business (2020-2025)
11.8.5 Merck Recent Development
11.9 GSK
11.9.1 GSK Company Details
11.9.2 GSK Business Overview
11.9.3 GSK Central Nervous System Disease Drugs Introduction
11.9.4 GSK Revenue in Central Nervous System Disease Drugs Business (2020-2025)
11.9.5 GSK Recent Development
11.10 Eli Lilly and Company
11.10.1 Eli Lilly and Company Company Details
11.10.2 Eli Lilly and Company Business Overview
11.10.3 Eli Lilly and Company Central Nervous System Disease Drugs Introduction
11.10.4 Eli Lilly and Company Revenue in Central Nervous System Disease Drugs Business (2020-2025)
11.10.5 Eli Lilly and Company Recent Development
11.11 Lundbeck
11.11.1 Lundbeck Company Details
11.11.2 Lundbeck Business Overview
11.11.3 Lundbeck Central Nervous System Disease Drugs Introduction
11.11.4 Lundbeck Revenue in Central Nervous System Disease Drugs Business (2020-2025)
11.11.5 Lundbeck Recent Development
11.12 Takeda
11.12.1 Takeda Company Details
11.12.2 Takeda Business Overview
11.12.3 Takeda Central Nervous System Disease Drugs Introduction
11.12.4 Takeda Revenue in Central Nervous System Disease Drugs Business (2020-2025)
11.12.5 Takeda Recent Development
11.13 Bristol Myers Squibb
11.13.1 Bristol Myers Squibb Company Details
11.13.2 Bristol Myers Squibb Business Overview
11.13.3 Bristol Myers Squibb Central Nervous System Disease Drugs Introduction
11.13.4 Bristol Myers Squibb Revenue in Central Nervous System Disease Drugs Business (2020-2025)
11.13.5 Bristol Myers Squibb Recent Development
11.14 Jiangsu Nhwa Pharmaceutical
11.14.1 Jiangsu Nhwa Pharmaceutical Company Details
11.14.2 Jiangsu Nhwa Pharmaceutical Business Overview
11.14.3 Jiangsu Nhwa Pharmaceutical Central Nervous System Disease Drugs Introduction
11.14.4 Jiangsu Nhwa Pharmaceutical Revenue in Central Nervous System Disease Drugs Business (2020-2025)
11.14.5 Jiangsu Nhwa Pharmaceutical Recent Development
11.15 Luye Pharma
11.15.1 Luye Pharma Company Details
11.15.2 Luye Pharma Business Overview
11.15.3 Luye Pharma Central Nervous System Disease Drugs Introduction
11.15.4 Luye Pharma Revenue in Central Nervous System Disease Drugs Business (2020-2025)
11.15.5 Luye Pharma Recent Development
11.16 Zhejiang Huahai Pharmaceutical
11.16.1 Zhejiang Huahai Pharmaceutical Company Details
11.16.2 Zhejiang Huahai Pharmaceutical Business Overview
11.16.3 Zhejiang Huahai Pharmaceutical Central Nervous System Disease Drugs Introduction
11.16.4 Zhejiang Huahai Pharmaceutical Revenue in Central Nervous System Disease Drugs Business (2020-2025)
11.16.5 Zhejiang Huahai Pharmaceutical Recent Development
11.17 Chengdu Easton Biopharmaceuticals
11.17.1 Chengdu Easton Biopharmaceuticals Company Details
11.17.2 Chengdu Easton Biopharmaceuticals Business Overview
11.17.3 Chengdu Easton Biopharmaceuticals Central Nervous System Disease Drugs Introduction
11.17.4 Chengdu Easton Biopharmaceuticals Revenue in Central Nervous System Disease Drugs Business (2020-2025)
11.17.5 Chengdu Easton Biopharmaceuticals Recent Development
11.18 Hansoh Pharmaceutical
11.18.1 Hansoh Pharmaceutical Company Details
11.18.2 Hansoh Pharmaceutical Business Overview
11.18.3 Hansoh Pharmaceutical Central Nervous System Disease Drugs Introduction
11.18.4 Hansoh Pharmaceutical Revenue in Central Nervous System Disease Drugs Business (2020-2025)
11.18.5 Hansoh Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
 Table 1. Global Central Nervous System Disease Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Antidepressants
 Table 3. Key Players of Antipsychotics
 Table 4. Key Players of Anti-Dementia Drugs
 Table 5. Key Players of Anti-Parkinson's Drugs
 Table 6. Key Players of Antiepileptic Drugs
 Table 7. Key Players of Others
 Table 8. Global Central Nervous System Disease Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 9. Global Central Nervous System Disease Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 10. Global Central Nervous System Disease Drugs Market Size by Region (2020-2025) & (US$ Million)
 Table 11. Global Central Nervous System Disease Drugs Market Share by Region (2020-2025)
 Table 12. Global Central Nervous System Disease Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 13. Global Central Nervous System Disease Drugs Market Share by Region (2026-2031)
 Table 14. Central Nervous System Disease Drugs Market Trends
 Table 15. Central Nervous System Disease Drugs Market Drivers
 Table 16. Central Nervous System Disease Drugs Market Challenges
 Table 17. Central Nervous System Disease Drugs Market Restraints
 Table 18. Global Central Nervous System Disease Drugs Revenue by Players (2020-2025) & (US$ Million)
 Table 19. Global Central Nervous System Disease Drugs Market Share by Players (2020-2025)
 Table 20. Global Top Central Nervous System Disease Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Central Nervous System Disease Drugs as of 2024)
 Table 21. Ranking of Global Top Central Nervous System Disease Drugs Companies by Revenue (US$ Million) in 2024
 Table 22. Global 5 Largest Players Market Share by Central Nervous System Disease Drugs Revenue (CR5 and HHI) & (2020-2025)
 Table 23. Global Key Players of Central Nervous System Disease Drugs, Headquarters and Area Served
 Table 24. Global Key Players of Central Nervous System Disease Drugs, Product and Application
 Table 25. Global Key Players of Central Nervous System Disease Drugs, Date of Enter into This Industry
 Table 26. Mergers & Acquisitions, Expansion Plans
 Table 27. Global Central Nervous System Disease Drugs Market Size by Type (2020-2025) & (US$ Million)
 Table 28. Global Central Nervous System Disease Drugs Revenue Market Share by Type (2020-2025)
 Table 29. Global Central Nervous System Disease Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 30. Global Central Nervous System Disease Drugs Revenue Market Share by Type (2026-2031)
 Table 31. Global Central Nervous System Disease Drugs Market Size by Application (2020-2025) & (US$ Million)
 Table 32. Global Central Nervous System Disease Drugs Revenue Market Share by Application (2020-2025)
 Table 33. Global Central Nervous System Disease Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 34. Global Central Nervous System Disease Drugs Revenue Market Share by Application (2026-2031)
 Table 35. North America Central Nervous System Disease Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 36. North America Central Nervous System Disease Drugs Market Size by Country (2020-2025) & (US$ Million)
 Table 37. North America Central Nervous System Disease Drugs Market Size by Country (2026-2031) & (US$ Million)
 Table 38. Europe Central Nervous System Disease Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 39. Europe Central Nervous System Disease Drugs Market Size by Country (2020-2025) & (US$ Million)
 Table 40. Europe Central Nervous System Disease Drugs Market Size by Country (2026-2031) & (US$ Million)
 Table 41. Asia-Pacific Central Nervous System Disease Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 42. Asia-Pacific Central Nervous System Disease Drugs Market Size by Region (2020-2025) & (US$ Million)
 Table 43. Asia-Pacific Central Nervous System Disease Drugs Market Size by Region (2026-2031) & (US$ Million)
 Table 44. Latin America Central Nervous System Disease Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 45. Latin America Central Nervous System Disease Drugs Market Size by Country (2020-2025) & (US$ Million)
 Table 46. Latin America Central Nervous System Disease Drugs Market Size by Country (2026-2031) & (US$ Million)
 Table 47. Middle East & Africa Central Nervous System Disease Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 48. Middle East & Africa Central Nervous System Disease Drugs Market Size by Country (2020-2025) & (US$ Million)
 Table 49. Middle East & Africa Central Nervous System Disease Drugs Market Size by Country (2026-2031) & (US$ Million)
 Table 50. Pfizer Company Details
 Table 51. Pfizer Business Overview
 Table 52. Pfizer Central Nervous System Disease Drugs Product
 Table 53. Pfizer Revenue in Central Nervous System Disease Drugs Business (2020-2025) & (US$ Million)
 Table 54. Pfizer Recent Development
 Table 55. Biogen Company Details
 Table 56. Biogen Business Overview
 Table 57. Biogen Central Nervous System Disease Drugs Product
 Table 58. Biogen Revenue in Central Nervous System Disease Drugs Business (2020-2025) & (US$ Million)
 Table 59. Biogen Recent Development
 Table 60. Otsuka Company Details
 Table 61. Otsuka Business Overview
 Table 62. Otsuka Central Nervous System Disease Drugs Product
 Table 63. Otsuka Revenue in Central Nervous System Disease Drugs Business (2020-2025) & (US$ Million)
 Table 64. Otsuka Recent Development
 Table 65. Novartis Company Details
 Table 66. Novartis Business Overview
 Table 67. Novartis Central Nervous System Disease Drugs Product
 Table 68. Novartis Revenue in Central Nervous System Disease Drugs Business (2020-2025) & (US$ Million)
 Table 69. Novartis Recent Development
 Table 70. Teva Pharmaceutical Company Details
 Table 71. Teva Pharmaceutical Business Overview
 Table 72. Teva Pharmaceutical Central Nervous System Disease Drugs Product
 Table 73. Teva Pharmaceutical Revenue in Central Nervous System Disease Drugs Business (2020-2025) & (US$ Million)
 Table 74. Teva Pharmaceutical Recent Development
 Table 75. Johnson & Johnson Company Details
 Table 76. Johnson & Johnson Business Overview
 Table 77. Johnson & Johnson Central Nervous System Disease Drugs Product
 Table 78. Johnson & Johnson Revenue in Central Nervous System Disease Drugs Business (2020-2025) & (US$ Million)
 Table 79. Johnson & Johnson Recent Development
 Table 80. AstraZeneca Company Details
 Table 81. AstraZeneca Business Overview
 Table 82. AstraZeneca Central Nervous System Disease Drugs Product
 Table 83. AstraZeneca Revenue in Central Nervous System Disease Drugs Business (2020-2025) & (US$ Million)
 Table 84. AstraZeneca Recent Development
 Table 85. Merck Company Details
 Table 86. Merck Business Overview
 Table 87. Merck Central Nervous System Disease Drugs Product
 Table 88. Merck Revenue in Central Nervous System Disease Drugs Business (2020-2025) & (US$ Million)
 Table 89. Merck Recent Development
 Table 90. GSK Company Details
 Table 91. GSK Business Overview
 Table 92. GSK Central Nervous System Disease Drugs Product
 Table 93. GSK Revenue in Central Nervous System Disease Drugs Business (2020-2025) & (US$ Million)
 Table 94. GSK Recent Development
 Table 95. Eli Lilly and Company Company Details
 Table 96. Eli Lilly and Company Business Overview
 Table 97. Eli Lilly and Company Central Nervous System Disease Drugs Product
 Table 98. Eli Lilly and Company Revenue in Central Nervous System Disease Drugs Business (2020-2025) & (US$ Million)
 Table 99. Eli Lilly and Company Recent Development
 Table 100. Lundbeck Company Details
 Table 101. Lundbeck Business Overview
 Table 102. Lundbeck Central Nervous System Disease Drugs Product
 Table 103. Lundbeck Revenue in Central Nervous System Disease Drugs Business (2020-2025) & (US$ Million)
 Table 104. Lundbeck Recent Development
 Table 105. Takeda Company Details
 Table 106. Takeda Business Overview
 Table 107. Takeda Central Nervous System Disease Drugs Product
 Table 108. Takeda Revenue in Central Nervous System Disease Drugs Business (2020-2025) & (US$ Million)
 Table 109. Takeda Recent Development
 Table 110. Bristol Myers Squibb Company Details
 Table 111. Bristol Myers Squibb Business Overview
 Table 112. Bristol Myers Squibb Central Nervous System Disease Drugs Product
 Table 113. Bristol Myers Squibb Revenue in Central Nervous System Disease Drugs Business (2020-2025) & (US$ Million)
 Table 114. Bristol Myers Squibb Recent Development
 Table 115. Jiangsu Nhwa Pharmaceutical Company Details
 Table 116. Jiangsu Nhwa Pharmaceutical Business Overview
 Table 117. Jiangsu Nhwa Pharmaceutical Central Nervous System Disease Drugs Product
 Table 118. Jiangsu Nhwa Pharmaceutical Revenue in Central Nervous System Disease Drugs Business (2020-2025) & (US$ Million)
 Table 119. Jiangsu Nhwa Pharmaceutical Recent Development
 Table 120. Luye Pharma Company Details
 Table 121. Luye Pharma Business Overview
 Table 122. Luye Pharma Central Nervous System Disease Drugs Product
 Table 123. Luye Pharma Revenue in Central Nervous System Disease Drugs Business (2020-2025) & (US$ Million)
 Table 124. Luye Pharma Recent Development
 Table 125. Zhejiang Huahai Pharmaceutical Company Details
 Table 126. Zhejiang Huahai Pharmaceutical Business Overview
 Table 127. Zhejiang Huahai Pharmaceutical Central Nervous System Disease Drugs Product
 Table 128. Zhejiang Huahai Pharmaceutical Revenue in Central Nervous System Disease Drugs Business (2020-2025) & (US$ Million)
 Table 129. Zhejiang Huahai Pharmaceutical Recent Development
 Table 130. Chengdu Easton Biopharmaceuticals Company Details
 Table 131. Chengdu Easton Biopharmaceuticals Business Overview
 Table 132. Chengdu Easton Biopharmaceuticals Central Nervous System Disease Drugs Product
 Table 133. Chengdu Easton Biopharmaceuticals Revenue in Central Nervous System Disease Drugs Business (2020-2025) & (US$ Million)
 Table 134. Chengdu Easton Biopharmaceuticals Recent Development
 Table 135. Hansoh Pharmaceutical Company Details
 Table 136. Hansoh Pharmaceutical Business Overview
 Table 137. Hansoh Pharmaceutical Central Nervous System Disease Drugs Product
 Table 138. Hansoh Pharmaceutical Revenue in Central Nervous System Disease Drugs Business (2020-2025) & (US$ Million)
 Table 139. Hansoh Pharmaceutical Recent Development
 Table 140. Research Programs/Design for This Report
 Table 141. Key Data Information from Secondary Sources
 Table 142. Key Data Information from Primary Sources
 Table 143. Authors List of This Report


List of Figures
 Figure 1. Central Nervous System Disease Drugs Picture
 Figure 2. Global Central Nervous System Disease Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Central Nervous System Disease Drugs Market Share by Type: 2024 VS 2031
 Figure 4. Antidepressants Features
 Figure 5. Antipsychotics Features
 Figure 6. Anti-Dementia Drugs Features
 Figure 7. Anti-Parkinson's Drugs Features
 Figure 8. Antiepileptic Drugs Features
 Figure 9. Others Features
 Figure 10. Global Central Nervous System Disease Drugs Market Size by Application (2020-2031) & (US$ Million)
 Figure 11. Global Central Nervous System Disease Drugs Market Share by Application: 2024 VS 2031
 Figure 12. Hospital and Clinic Case Studies
 Figure 13. Pharmacy Case Studies
 Figure 14. Central Nervous System Disease Drugs Report Years Considered
 Figure 15. Global Central Nervous System Disease Drugs Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 16. Global Central Nervous System Disease Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 17. Global Central Nervous System Disease Drugs Market Share by Region: 2024 VS 2031
 Figure 18. Global Central Nervous System Disease Drugs Market Share by Players in 2024
 Figure 19. Global Top Central Nervous System Disease Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Central Nervous System Disease Drugs as of 2024)
 Figure 20. The Top 10 and 5 Players Market Share by Central Nervous System Disease Drugs Revenue in 2024
 Figure 21. North America Central Nervous System Disease Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. North America Central Nervous System Disease Drugs Market Share by Country (2020-2031)
 Figure 23. United States Central Nervous System Disease Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Canada Central Nervous System Disease Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. Europe Central Nervous System Disease Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. Europe Central Nervous System Disease Drugs Market Share by Country (2020-2031)
 Figure 27. Germany Central Nervous System Disease Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. France Central Nervous System Disease Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. U.K. Central Nervous System Disease Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Italy Central Nervous System Disease Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Russia Central Nervous System Disease Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Nordic Countries Central Nervous System Disease Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Asia-Pacific Central Nervous System Disease Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Asia-Pacific Central Nervous System Disease Drugs Market Share by Region (2020-2031)
 Figure 35. China Central Nervous System Disease Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Japan Central Nervous System Disease Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. South Korea Central Nervous System Disease Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Southeast Asia Central Nervous System Disease Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. India Central Nervous System Disease Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Australia Central Nervous System Disease Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Latin America Central Nervous System Disease Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Latin America Central Nervous System Disease Drugs Market Share by Country (2020-2031)
 Figure 43. Mexico Central Nervous System Disease Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Brazil Central Nervous System Disease Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Middle East & Africa Central Nervous System Disease Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Middle East & Africa Central Nervous System Disease Drugs Market Share by Country (2020-2031)
 Figure 47. Turkey Central Nervous System Disease Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. Saudi Arabia Central Nervous System Disease Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 49. UAE Central Nervous System Disease Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 50. Pfizer Revenue Growth Rate in Central Nervous System Disease Drugs Business (2020-2025)
 Figure 51. Biogen Revenue Growth Rate in Central Nervous System Disease Drugs Business (2020-2025)
 Figure 52. Otsuka Revenue Growth Rate in Central Nervous System Disease Drugs Business (2020-2025)
 Figure 53. Novartis Revenue Growth Rate in Central Nervous System Disease Drugs Business (2020-2025)
 Figure 54. Teva Pharmaceutical Revenue Growth Rate in Central Nervous System Disease Drugs Business (2020-2025)
 Figure 55. Johnson & Johnson Revenue Growth Rate in Central Nervous System Disease Drugs Business (2020-2025)
 Figure 56. AstraZeneca Revenue Growth Rate in Central Nervous System Disease Drugs Business (2020-2025)
 Figure 57. Merck Revenue Growth Rate in Central Nervous System Disease Drugs Business (2020-2025)
 Figure 58. GSK Revenue Growth Rate in Central Nervous System Disease Drugs Business (2020-2025)
 Figure 59. Eli Lilly and Company Revenue Growth Rate in Central Nervous System Disease Drugs Business (2020-2025)
 Figure 60. Lundbeck Revenue Growth Rate in Central Nervous System Disease Drugs Business (2020-2025)
 Figure 61. Takeda Revenue Growth Rate in Central Nervous System Disease Drugs Business (2020-2025)
 Figure 62. Bristol Myers Squibb Revenue Growth Rate in Central Nervous System Disease Drugs Business (2020-2025)
 Figure 63. Jiangsu Nhwa Pharmaceutical Revenue Growth Rate in Central Nervous System Disease Drugs Business (2020-2025)
 Figure 64. Luye Pharma Revenue Growth Rate in Central Nervous System Disease Drugs Business (2020-2025)
 Figure 65. Zhejiang Huahai Pharmaceutical Revenue Growth Rate in Central Nervous System Disease Drugs Business (2020-2025)
 Figure 66. Chengdu Easton Biopharmaceuticals Revenue Growth Rate in Central Nervous System Disease Drugs Business (2020-2025)
 Figure 67. Hansoh Pharmaceutical Revenue Growth Rate in Central Nervous System Disease Drugs Business (2020-2025)
 Figure 68. Bottom-up and Top-down Approaches for This Report
 Figure 69. Data Triangulation
 Figure 70. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Novocure

SIMILAR REPORTS

OSZAR »